Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2022; 18: e-20220305
DOI: 10.5935/2526-8732.20220305
Review Article
Clinical Oncology

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0

Diretrizes brasileiras atualizadas para o manejo de eventos adversos relacionados ao sistema imunológico associados aos inibidores de checkpoint - edição 2.0
Aknar Calabrich
Clínica AMO - Salvador
,
Alberto Julius Wainstein
Faculdade de Ciências Médicas de Minas Gerais e Hospital Mater Dei - Belo Horizonte
,
Andréia Cristina de Melo
Instituto Nacional de Câncer e Grupo Oncoclínicas - Rio de Janeiro
,
Antonio Carlos Buzaid
Beneficência Portuguesa de São Paulo - São Paulo
,
Artur Katz
Hospital Sírio Libanês - São Paulo
,
Carlos Gil Ferreira
Instituto D'Or de Pesquisa - Rio de Janeiro
,
Carlos Henrique dos Anjos
Hospital Sírio Libanês - São Paulo
,
Clarissa Baldotto
Oncologia D'Or- Rio de Janeiro
,
Clarissa Maria de Cerqueira Mathias
NOB/Oncoclínicas - Salvador
,
Elimar Elias Gomes
Beneficência Portuguesa de São Paulo - São Paulo
,
Fernando Moura
Hospital Israelita Albert Einstein - São Paulo
,
Gilberto de Castro Junior
Hospital Sírio Libanês e Instituto do Câncer do Estado de São Paulo - São Paulo
,
Guilherme Harada
Hospital Sírio Libanês - São Paulo
,
Guilherme Nader Marta
Institut Jules Bordet - Université Libre de Bruxelles
,
Gustavo dos Santos Fernandes
Hospital Sírio Libanês - Brasília
,
Luiza Dib Batista Bugiato Faria
Hospital Sírio Libanês - Brasília
,
Mariana Laloni
Centro Paulista de Oncologia - São Paulo
,
Paulo Marcelo Gehm Hoff
Oncologia D'Or e Instituto do Câncer do Estado de São Paulo - São Paulo
,
Rodrigo Ramella Munhoz
Hospital Sírio Libanês e Instituto do Câncer do Estado de São Paulo - São Paulo
,
Romualdo Barroso-Sousa
Hospital Sírio Libanês - Brasília
,
Sergio Jobim de Azevedo
Grupo Oncoclínicas e Hospital de Clínicas de Porto Alegre - Porto Alegre
,
Vladmir Cláudio Cordeiro de Lima
Oncologia D'Or São Paulo e Instituto do Câncer do Estado de São Paulo
,
William Nassib William Junior
Beneficência Portuguesa de São Paulo - São Paulo
,
Rodrigo Ramella Munhoz
Sociedade Brasileira de Oncologia Clínica, Hospital Sírio Libanês
,
Clarissa Maria de Cerqueira Mathias
Sociedade Brasileira de Oncologia Clínica
,
Guilherme Harada
Hospital Sírio Libanês - São Paulo) Renan Orsati Clara (Sociedade Brasileira de Oncologia Clínica)
› Author Affiliations Financial support: This update was funded by the Brazilian Society of Clinical Oncology.
› Further Information
   Permissions and Reprints All articles of this category

ABSTRACT

Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies. Over the past years, evidences supporting the clinical use of IT both in monotherapy, as well as in combinatorial regimens, grew dramatically, leading to multiple regulatory approvals. With the expanding clinical incorporation of IT, understanding the mechanisms and management of the adverse events (AE) associated with this class of drugs is of utmost importance for professionals involved in patient care. In 2017, the Brazilian Society of Clinical Oncology (SBOC) issued the initial version of the “Brazilian guidelines for the management of immune-related toxicities associated with checkpoint inhibitors”. In this article, we aimed to update general and specific aspects related to immune-related AEs associated with the use of immune-checkpoint inhibitors, including emerging evidences and updated algorithms for the most frequent clinical manifestations.

RESUMO

A imunoterapia (IT) na forma de anticorpos monoclonais direcionados a correceptores envolvidos na modulação da sinapse imune, representa um padrão de tratamento para pacientes com neoplasias distintas. Nos últimos anos, as evidências que apoiam o uso clínico da TI tanto em monoterapia quanto em regimes combinatórios cresceram dramaticamente, levando a várias aprovações regulatórias. Com a crescente incorporação clínica da TI, entender os mecanismos e o manejo dos eventos adversos (EA) associados a essa classe de medicamentos é de extrema importância para os profissionais envolvidos no cuidado ao paciente. Em 2017, a Sociedade Brasileira de Oncologia Clínica (SBOC) publicou a versão inicial das “Diretrizes brasileiras para o manejo de toxicidades imunorrelacionadas associadas a inibidores de checkpoint”. Neste artigo, buscamos atualizar aspectos gerais e específicos relacionados aos EAs relacionados ao sistema imunológico associados ao uso de inibidores de checkpoint imunológico, incluindo evidências emergentes e algoritmos atualizados para as manifestações clínicas mais frequentes.

Headings:

Immunotherapy - Practice guideline - Adverse effects - Immune-checkpoint inhibitors

Descritores:

Imunoterapia - Orientação prática - Efeitos adversos - Inibidores de checkpoint imunológico

* Brazilian Society of Clinical Oncology Task Force.




Publication History

Received: 13 October 2021

Accepted: 15 October 2021

Article published online:
06 May 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Aknar Calabrich, Alberto Julius Wainstein, Andréia Cristina de Melo, Antonio Carlos Buzaid, Artur Katz, Carlos Gil Ferreira, Carlos Henrique dos Anjos, Clarissa Baldotto, Clarissa Maria de Cerqueira Mathias, Elimar Elias Gomes, Fernando Moura, Gilberto de Castro, Guilherme Harada, Guilherme Nader Marta, Gustavo dos Santos Fernandes, Luiza Dib Batista Bugiato Faria, Mariana Laloni, Paulo Marcelo Gehm Hoff, Rodrigo Ramella Munhoz, Romualdo Barroso-Sousa, Sergio Jobim de Azevedo, Vladmir Cláudio Cordeiro de Lima, William Nassib William, Rodrigo Ramella Munhoz, Clarissa Maria de Cerqueira Mathias, Guilherme Harada. Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0. Brazilian Journal of Oncology 2022; 18: e-20220305.
DOI: 10.5935/2526-8732.20220305
 

  • REFERENCES

  • 1 Hodi FS, Kluger H, Sznol M, Carvajal R, Lawrence D, Atkins M. et al. Abstract CT001: durable, longterm survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Cancer Res 2016; 76 (14 Suppl): CT001
    Search in Google Scholar
  • 2 Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; Apr; 315 (15) 1600-1609
    Search in Google Scholar
  • 3 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; Jun; 372 (26) 2509-2520
    Search in Google Scholar
  • 4 Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; Jul; 373 (02) 123-135
    Search in Google Scholar
  • 5 Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; May; 387 (10031): 1909-1920
    Search in Google Scholar
  • 6 Wainstein AJ, Calabrich A, Melo AC, Buzaid AC, Katz A, Anjos CA. et al. Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors. Braz J Oncol. 2017;13(2017)
  • 7 Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019; Nov; 7 (01) 306
    Search in Google Scholar
  • 8 Postow MA, Sidlow R, Hellmann MD. Immunerelated adverse events associated with immune checkpoint blockade. N Engl J Med 2018; Jan; 378 (02) 158-168
    Search in Google Scholar
  • 9 Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X. et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019; Jul; 5 (07) 1008-1019
    Search in Google Scholar
  • 10 Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 2016; Jul; 11 (07) e0160221
    Search in Google Scholar
  • 11 Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G. et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol 2020; Mar; 6 (03) 375-384
    Search in Google Scholar
  • 12 Champiat S, Lambreiotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; Apr; 27 (04) 559-574
    Search in Google Scholar
  • 13 Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; Aug; 13 (08) 473-486
    Search in Google Scholar
  • 14 Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; Jun; 372 (26) 2521-2532
    Search in Google Scholar
  • 15 Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; Jul; 373 (01) 23-34
    Search in Google Scholar
  • 16 Carretero-González A, Lora D, Ghanem I, Otero I, López F, Castellano D. et al. Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials. Oncotarget 2019; 10 (35) 3294-3301
    Search in Google Scholar
  • 17 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; Aug; 363 (08) 711-723
    Search in Google Scholar
  • 18 Weber JS, Antonia SJ, Topalian SL, Schadendorf D, Larkin JMG, Sznol M. et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. J Clin Oncol 2015; 33 (15 Suppl): 9018
    Search in Google Scholar
  • 19 Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Antiangiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol 2020; 11: 1956
    Search in Google Scholar
  • 20 Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018; Dec; 4 (12) 1721-1728
    Search in Google Scholar
  • 21 Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 2020; Apr; 18 (01) 87
    Search in Google Scholar
  • 22 Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Vareki SM. et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev 2021; Jan; 92: 102134
    Search in Google Scholar
  • 23 Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; Feb; 54: 139-148
    Search in Google Scholar
  • 24 Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; Jun; 33 (18) 2092-2099
    Search in Google Scholar
  • 25 Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; Jun; 18 (06) 733-743
    Search in Google Scholar
  • 26 Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J. et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res 2016; 26 (05) 469-480
    Search in Google Scholar
  • 27 Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V. et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; Apr; 45: 7-18
    Search in Google Scholar
  • 28 Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L. et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 2018; Jul; 36 (19) 1905-1912
    Search in Google Scholar
  • 29 Abdel-Wahab N, Shah M, Lopez-Olivo MA, SuarezAlmazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med 2018; Jan; 168 (02) 121-130
    Search in Google Scholar
  • 30 Laura CK, Shailender B, John AT, Petros G. Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Canc Netw 2019; Jun; 17 (06) 750-757
    Search in Google Scholar
  • 31 Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M. et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 2019; Jun; 24 (06) e327-e37
    Search in Google Scholar
  • 32 Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed deathligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018; Oct; 36 (28) 2872-2878
    Search in Google Scholar
  • 33 Drakaki A, Luhn P, Wakelee H, Dhillon PK, Kent M, Shim J. et al. Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, nonsmall cell lung cancer or urothelial cancer in routine clinical practice. Ann Oncol 2019; Dec; 30 (Suppl 11): xi16-xi7
    Search in Google Scholar
  • 34 Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015; Oct; 33 (28) 3193-3198
    Search in Google Scholar
  • 35 Weber JS, Larkin JMG, Schadendorf D, Wolchok JD, Wagstaff J, Dummer R. et al. Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). J Clin Oncol 2017; 35 (15 Suppl): 9523
    Search in Google Scholar
  • 36 Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P. et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017; Dec; 35 (34) 3807-3814
    Search in Google Scholar
  • 37 Leighl N, Gandhi L, Hellmann MD, Horn L, Ahn MJ, Garon EB. et al. Pembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use. J Thorac Oncol 2015; 10: S233
    Search in Google Scholar
  • 38 Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA. et al. Ipilimumab administration for advanced melanoma in patients with preexisting Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer 2014; Oct; 2 (01) 33
    Search in Google Scholar
  • 39 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; Jun; 389 (10088): 2492-2502
    Search in Google Scholar
  • 40 Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol 2019; Jul; 5 (07) 1049-1054
    Search in Google Scholar
  • 41 Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014; Jul; 32 (19) e69-e71
    Search in Google Scholar
  • 42 Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM. et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019; Apr; 7 (01) 106
    Search in Google Scholar
  • 43 Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev 2016; Apr; 45: 30-37
    Search in Google Scholar
  • 44 Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer 2018; Apr; 6 (01) 26
    Search in Google Scholar
  • 45 Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 2015; Feb; 26 (02) 288-300
    Search in Google Scholar
  • 46 Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A. et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 2019; Jun; 5 (09) 1310-1317
    Search in Google Scholar
  • 47 Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M. et al. Safety and efficacy of re-treating with immunotherapy after immunerelated adverse events in patients with NSCLC. Cancer Immunol Res 2018; Sep; 6 (09) 1093-1099
    Search in Google Scholar
  • 48 Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; Mar; 44: 51-60
    Search in Google Scholar
  • 49 Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; Dec; 26 (12) 2375-2391
    Search in Google Scholar
  • 50 Weber JS, Dummer R, Pril V, Lebbé C, Hodi FS. MDX1020 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer 2013; May; 119 (09) 1675-1682
    Search in Google Scholar
  • 51 Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi PD-1 C.. inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis'. Histopathology 2017; Mar; 70 (04) 558-567
    Search in Google Scholar
  • 52 Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M. et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019; Apr; 7 (01) 93
    Search in Google Scholar
  • 53 Foppen MHG, Rozeman EA, Van Wilpe S, Postma C, Snaebjornsson P, Van Thienen JV. et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018; Jan; 3 (01) e000278
    Search in Google Scholar
  • 54 Zou F, Shah A, Glitza IC, Richards D, Thomas AS, Wang Y. Comparative study of vedolizumab and infliximab treatment in patients with immune-mediated diarrhea and colitis. Am Coll Gastroenterol 2020; Oct; 115: S68
    Search in Google Scholar
  • 55 Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S. et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017; May; 66 (05) 58192
    Search in Google Scholar
  • 56 Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017; Feb; 8: 49
    Search in Google Scholar
  • 57 Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; May; 372 (21) 200617
    Search in Google Scholar
  • 58 Peeraphatdit T, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology 2020; Jul; 72 (01) 315-329
    Search in Google Scholar
  • 59 Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist 2018; Sep; 23 (09) 991-997
    Search in Google Scholar
  • 60 Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA. et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 2018; Dec; 13 (12) 1930-1939
    Search in Google Scholar
  • 61 Shimokawaji T, Narita S, Naito T, Udagawa H, Goto K, Miyawaki T. et al. Clinical characteristics of nivolumab-induced radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real-world analysis of 669 patients. J Clin Oncol 2020; 38 (5 Suppl): 88
    Search in Google Scholar
  • 62 Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC. et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; Jul; 18 (07) 895-903
    Search in Google Scholar
  • 63 Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; Dec; 379 (24) 2342-2350
    Search in Google Scholar
  • 64 Sibaud V. Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol 2018; Jun; 19 (03) 345-361
    Search in Google Scholar
  • 65 Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A. et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 2019; Oct; 37 (30) 2746-2758
    Search in Google Scholar
  • 66 Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE. et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; Feb; 4 (02) 173-182
    Search in Google Scholar
  • 67 Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI. et al. Vitiligo-like depigmentation in patients with STAGE III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; Mar; 33 (07) 773-781
    Search in Google Scholar
  • 68 Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C. et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol 2017; Apr; 86 (04) 614-620
    Search in Google Scholar
  • 69 Cukier P, Santini FC, Scaranti M, Hoff AO. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 2017; Dec; 24 (12) T331-T47
    Search in Google Scholar
  • 70 Clotman K, Janssens K, Specenier P, Weets I, Block CEM. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab 2018; Sep; 103 (09) 3144-3154
    Search in Google Scholar
  • 71 Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; Nov; 375 (18) 1749-1755
    Search in Google Scholar
  • 72 Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med 2019; Mar; 5 (01) 6-14
    Search in Google Scholar
  • 73 Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK. et al. Hematologic complications of immune checkpoint inhibitors. Oncologist 2019; May; 24 (05) 584-588
    Search in Google Scholar
  • 74 Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; Jan; 372 (04) 311-319
    Search in Google Scholar
  • 75 Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 2017; Mar; 73: 1-8
    Search in Google Scholar
  • 76 Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP. et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 2017; Oct; 74 (10) 1216-1222
    Search in Google Scholar
  • 77 Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E. et al. Neurotoxicity from immunecheckpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 2017; Feb; 28 (02) 377-385
    Search in Google Scholar
  • 78 Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 2017; Dec; 13 (12) 755-763
    Search in Google Scholar
  • 79 Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 2017; Apr; 69 (04) 687-699
    Search in Google Scholar
  • 80 Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and musculoskeletal immunerelated adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res 2017; Nov; 69 (11) 1751-1763
    Search in Google Scholar
  • 81 Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B. et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 2017; Oct; 76 (10) 1747-1750
    Search in Google Scholar
  • 82 Benesova K, Lorenz HM, Leipe J, Jordan K. How I treat cancer: treatment of rheumatological side effects of immunotherapy. ESMO Open 2019; Jul; 4 (Suppl 4): e000529
    Search in Google Scholar
  • 83 Benesova K, Diekmann L, Lorenz HM, Leipe J, Kunz J, Hassel JC. et al. 1809O TRheuMa registry provides real world data on rheumatic immunerelated adverse events. Ann Oncol 2020; Set; 31 (Suppl 4): S1046
    Search in Google Scholar
  • 84 Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol 2019; Jun; 31 (03) 319-322
    Search in Google Scholar
  • 85 Bomze D, Meirson T, Hasan Ali O, Goldman A, Flatz L, Habot-Wilner Z. Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis. Ocular Immunol Inflamm 2020; Aug; 1-7
    Search in Google Scholar
  • 86 Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncol 2019; Nov; 5 (11) 1633-1635
    Search in Google Scholar
  • 87 Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y. et al. Multiomics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun 2020; Oct; 11 (01) 4946
    Search in Google Scholar